Reviva Pharmaceuticals Holdings Inc RVPH

Healthcare Biotechnology

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

NDAQ:RVPH - Post by User

Reviva Pharmaceuticals Holdings Inc

<< Previous

Bullboard Posts

Next >>

(69)
•••

Comment by Iseneschalon Apr 27, 2021 10:32am

69 Views

Post# 33073872

RE:Marking new "Strike 2" pivot......

Iseneschal wrote: which is now $8.03 and has just been breached..... Strike 3 is a tough call but I will go out on a limb and say it's game over sub- $7...... time will tell

And there you have it folks............after yesterdays action.....sub $7.00 this a.m

Cheers !

<< Previous

Bullboard Posts

Next >>

AtkinsRéalis JV signs multi-billion-dollar contract for nuclear life extension